On September 5, 2022 Herantis Pharma Plc, reported An aggregate number of 2,400 new shares of Herantis Pharma Plc ("Herantis") have been subscribed for with option rights under the option program 2010 (Press release, Herantis Pharma, SEP 5, 2022, View Source,c3625675 [SID1234618981]). The new shares have been registered with the trade register maintained by the Finnish Patent and Registration Office today. The new shares will confer shareholder rights in Herantis after they have been issued in the book-entry system, on or about 2 September 2022.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Trading with the new shares is expected to commence on the Nasdaq First North Growth Market Finland marketplace on or about 6 September 2022, provided that Nasdaq Helsinki Ltd approves the listing application submitted by Herantis.

As a result of the share subscriptions, the total number of shares in Herantis will increase to 16,912,394.